---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-002828"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T08:51:38.446240+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants Revelation continued listing subject to reverse split and $1 price by Feb 14, 2025

## Summary
- Nasdaq Panel granted continued listing; must effect reverse stock split by Jan 31, 2025.
- Must maintain $1.00 bid price for 10 consecutive trading days by Feb 14, 2025.
- Regained compliance with Nasdaq equity requirement (Rule 5550(b)(1)).
- Company raised $4M from warrant exercise in December 2024.
- FDA accepted Gemini IND; Phase 1b study in chronic kidney disease expected H1 2025.

## SEC filing metadata
- accession: 0000950170-25-002828
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017025002828/0000950170-25-002828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017025002828/revb-20250103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-002828
- JSON: https://secwatch.observer/filing/0000950170-25-002828.json
- Plain text: https://secwatch.observer/filing/0000950170-25-002828.txt

## Key facts
- Listing & Compliance Notices
  REVELATION BIOSCIENCES, INC. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: compliance regained
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: January 3, 2025, Revelation Biosciences, Inc. (the “Company”) received a decision letter issued by the Nasdaq Hearings Panel granting the Company’s request to continue its listing on The Nasdaq Stock Market, subject to e
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017025002828/0000950170-25-002828-index.htm
- Listing & Compliance Notices
  REVELATION BIOSCIENCES, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: January 3, 2025, Revelation Biosciences, Inc. (the “Company”) received a decision letter issued by the Nasdaq Hearings Panel granting the Company’s request to continue its listing on The Nasdaq Stock Market, subject to e
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017025002828/0000950170-25-002828-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.